NEW YORK, Oct. 19, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Biobanking: Technologies and Global Markets
http://www.reportlinker.com/p0568365/Biobanking-Technologies-and-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biotechnology
REPORT HIGHLIGHTS
THIS REPORT CONTAINS
* An overview of biobanks by types: Population, Disease, and Private Sector
* Analysis of global market trends, with data from 2009, estimates for 2010, and projections of compound annual growth rates (CAGRs) through 2015
* A geographic breakdown of the markets that will cover the U.S., the European Union, Asia, and the rest of the world
* Examinations of applications detailed by Biomarker Identification, Recurrence Risk, Sample Storage, Predisposition Risk, and Trial Effectiveness
* Discussion of regulatory dynamics, intellectual property, and ethical considerations
* Comprehensive company profiles of major players.
INTRODUCTION
STUDY GOALS AND OBJECTIVES
This market research report provides a comprehensive sizing, forecast, and analysis of the global market for "biobanking," the storage of biological samples for the future.
The report will review global markets for biobank products and will forecast trends and sales in these markets through 2015. The report provides a range of information, from detailed analyses of how biobanks can lead to new products for specific diseases to overall industry trends. This information will allow the reader to evaluate and quantify the current market size for specific biobank services within the overall growing biomedical/pharmaceutical technology market.
Forecasts and trends have been developed from a variety of data, including industry sources, company publications, industry benchmarks, and other data sources. Major biobank repositories, technologies, geography, and factors influencing the demand for biobanks will be discussed. Consideration is given to an analysis of government issues versus the biotech/pharmaceutical industry markets.
REASONS FOR DOING THE STUDY
The biobanking market presents the largest of all opportunities in the area of new drug and treatment development for specific diseases. This study investigates one of the most important market drivers in the biotech/pharma area: the INTRODUCTION to the market of a resource for investigating a variety of combined disease therapies. This is expected to contribute substantially to market growth through the forecast period. This report analyzes emerging biobanking markets, by specific disease segment and specific application. Continued worldwide growth is expected due the growing middle class in emerging countries such as India, China, Brazil, and Russia.
This report addresses the critically important topics of analyzing a changing market dynamic, the emerging players and technologies, strategies for accessing these emerging markets, and measurement and forecast of specific disease segments and geographies to allow for enhanced resource allocation.
SCOPE OF REPORT
Current and projected biobank product forecasts during the forecast period (2010 to 2015) are discussed. Biobanks are playing an important role in new drug development. New products approved by the FDA in 2009 and 2010 are covered, and those products expected to be approved within the forecast period are projected. Due to the timing of the release of this report, the figures for 2010 are estimated, except where actual results have been reported.
The report includes analysis of the leading competitors, as well as emerging companies in the current worldwide biobanking market. Profiles of the manufacturers of the leading products are analyzed, and their specific product strategies are outlined. This analysis also includes biotechnology companies that are using biobanks to develop new, novel products. This report looks at companies poised to introduce new products during the forecast period and discusses how these products may change the face of the competitive environment. This competitive environment is examined with a special focus on how developing products and technologies are influencing the current standard of patient care. Detailed profiles of the current market leaders and emerging companies are discussed in detail.
Market figures are based on revenues at the manufacturers' level, and the base year for analysis and projection is 2010. Inflation is not calculated in the projection figures. Trends are assessed based on a number of parameters, including projected sales for existing products, new product INTRODUCTIONs, expanded indications for existing products, and finally, for projected changes in the prevalence, diagnosis, and prescription rates for certain diseases.
Included in this report are an overview and forecast of the biobanking market by product, disease category, geographic region or country, and company for the period of 2009 to 2015. The worldwide market is analyzed and data are provided for each disease subsegment. Excluded from this report are over-the-counter (OTC) medications, and other consumables that do not require a physician's prescription.
Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.
All market share data presented is on a global basis, unless specifically noted.
INTENDED AUDIENCE
This report is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investors, investor consultants, and anyone interested in the biobanking market, its products, industry participants, and future.
The importance of identifying overall market trends, product opportunities, emerging geographies, merger and acquisition opportunities, and insights that provide guidance for sales growth and business decisions for a variety of reasons, including the following:
* Established companies in the industry will benefit from the contents of this report, including corporate strategy, sales and marketing, business development, and R&D.
* Emerging biotechnology players must understand specific opportunities for out-licensing, originating from the differentiation of their biomarker product or technology as compared to leading, competitive, and emerging therapies. In addition, the market forecasts found in this study are supported in detail.
* Investment firms evaluating candidates for venture capital or investment in hedge funds will gain insights into the opportunity and risks encountered in the industry, with a product- and company-specific analysis.
* Equity analysts are provided with detailed forecasts for the next 5 years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long run.
METHODOLOGY AND INFORMATION SOURCES
Both primary and secondary research methodologies were used in preparing this report. In-depth interviews were conducted with leading experts in the field, including company executives, industry analysts, and leading medical practitioners.
The overall biobanking sector comprises a variety of fast growing and independent segments. For completeness, the current and forecasted markets comprise the total market for each respective segment. Within each subsection, there is a detailed forecast of each market driver or relevant area of growth.
The information used in preparing this report was obtained from emerging companies involved the biobanking industry, including their annual reports and 10-Ks. Information was also retrieved from articles published in medical journals such as the American Heart Journal, Circulation, Journal of BioBanks Pharmacology, Lancet, and others, governmental agencies such as the World Health Organization (WHO) and the National Heart, Lung and Blood Institute (NHLBI), and nonprofit organizations such as the American Heart Association. Population estimates are based on those reported by the U.S. Census Bureau's international database.
Current and historical revenue figures for individual products have been sourced from company disclosures that exist in the public domain or from government sources.
CHAPTER ONE INTRODUCTION ... 1
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY .. 1
SCOPE OF REPORT 2
INTENDED AUDIENCE .... 2
METHODOLOGY AND INFORMATION SOURCES .... 3
RELATED BCC REPORTS 4
BCC ONLINE SERVICES .. 4
DISCLAIMER . 4
CHAPTER TWO: SUMMARY 5
SUMMARY TABLE GLOBAL BIOBANKING REVENUES FORECAST
BY SEGMENT, THROUGH 2015 ($ MILLIONS) .... 5
SUMMARY FIGURE GLOBAL BIOBANKING REVENUES FORECAST
BY SEGMENT, 2009-2015 ($ MILLIONS) . 6
SUMMARY (CONTINUED) .... 7
CHAPTER THREE: OVERVIEW .... 8
CURRENT STATE OF THE INDUSTRY ... 8
THE PROCESS OF BIOBANKING .. 9
HISTORICAL CONTEXT . 10
SCIENTIFIC AND COMMERCIAL RELEVANCE OF BIOBANKS ... 11
SCIENTIFIC AND COMMERCIAL … (CONTINUED) ... 12
TABLE 1 CUMULATIVE NUMBER OF DNA SAMPLES BANKED IN
POPULATION-BASED STUDIES*, 1970–2009 (RECRUITMENT
START DATE) .... 13
TABLE 2 VALUE OF DNA SAMPLES STORED, THROUGH 2015 ($
MILLIONS) .... 13
TABLE 3 NIH-SPONSORED CLINICAL TRIALS CONDUCTING GENE
EXPRESSION PROFILING, 2000–2008 (NO.) ... 14
MODERN BIOBANKS – PUBLIC SECTOR . 14
POPULATION-BASED BIOBANKS ... 14
DISEASE-BASED BIOBANKS . 15
BIOBANKING COSTS 16
DRIVERS OF BIOBANKS EXPANSION . 17
BARRIERS TO BIOBANKS EXPANSION .... 17
BIOBANKING TRENDS AND FORECAST .. 18
FORECAST FOR BIOBANK INVOLVEMENT IN FUTURE
BIOMEDICAL DISCOVERIES .. 19
FORECAST FOR BIOBANK … (CONTINUED) .... 20
FORECAST FOR BIOBANK … (CONTINUED) .... 21
CHAPTER FOUR: OVERVIEW OF BIOBANK APPLICATIONS .. 22
TYPES OF BIOBANK APPLICATIONS .. 22
TABLE 4 GLOBAL BIOBANKING MARKET BY APPLICATION,
THROUGH 2015 ($ MILLIONS) . 22
BIOMARKERS ... 23
TABLE 5 SELECTED U.S. CANCER BIOBANKS . 23
TABLE 6 GLOBAL MARKET FORECAST OF BIOMARKERS IN LATESTAGE
CLINICAL USE BY THERAPEUTIC AREA, THROUGH 2015
($ MILLIONS) 24
OPPORTUNITIES IN CANCER 24
TABLE 7 APPLICATIONS OF BIOMARKERS FOR CANCER
TREATMENTS ... 25
OPPORTUNITIES IN CANCER (CONTINUED) ... 26
TABLE 8 REPRESENTATIVE BIOMARKERS IN GLOBAL CLINICAL
USE: ONCOLOGY ... 27
OPPORTUNITIES IN CARDIOVASCULAR DISEASE ... 28
TABLE 9 REPRESENTATIVE BIOMARKERS IN U.S. CLINICAL USE:
CARDIOVASCULAR .... 29
OPPORTUNITIES IN NEUROLOGICAL DISEASES 29
BRAIN AND CENTRAL NERVOUS SYSTEM DISORDERS ... 29
Depression .... 29
Major Depressive Disorder ... 30
Adult Attention-Deficit/Hyperactivity Disorder 30
Schizophrenia ... 31
TABLE 10 REPRESENTATIVE BIOMARKERS IN GLOBAL CLINICAL
USE: CNS DISEASE .... 31
Alzheimer's Disease .... 32
OPPORTUNITIES IN IMMUNOLOGY .... 32
AUTOIMMUNE DISEASES . 32
TABLE 11 REPRESENTATIVE BIOMARKERS IN GLOBAL CLINICAL
USE: IMMUNOLOGY .. 33
Systemic Lupus Erythematosus .... 33
OTHER OPPORTUNITIES RESULTING FROM BIOBANKS .. 33
TARGETED THERAPEUTICS . 33
DIAGNOSTIC AND PROGNOSTIC TESTS . 34
Diagnostic Tests 35
Prognostic Tests 35
DRUG DEVELOPMENT . 36
DISEASE ETIOLOGY . 37
Disease Etiology (Continued) .... 38
CHAPTER FIVE: BIOBANKS WORLDWIDE ... 39
OVERVIEW ... 39
FIGURE 1 WORLDWIDE LOCATION OF MAJOR BIOBANKS .... 39
FIGURE 1 (CONTINUED) 40
TABLE 12 TYPES OF BIOBANKS (NO.) . 40
U.S. BIOBANKS 40
TABLE 13 MAJOR NHLBI COHORT STUDIES ... 41
TABLE 14 EXAMPLES OF MAJOR DISEASE-BASED BIOBANKS . 41
EUROPEAN BIOBANKS . 42
THE UNITED KINGDOM .... 42
U.K. Biobank 43
Licensed Biobanks in the U.K. .. 43
TABLE 15 BIOBANKS LICENSED TO OPERATE IN THE U.K. BY
TYPE OF OWNERSHIP, 2008 (NO.) .... 44
TABLE 16 FUNDING SOURCES FOR BIOBANKS LICENSED IN THE
U.K. BY TYPE, 2009/2010 (%) .... 44
BBMRI 45
TABLE 17 COMPOSITE FUNDING METHODS FOR BIOBANKS IN
BBMRI COUNTRIES BY SOURCE, 2010 (%) .... 46
TABLE 18 JOINT RESEARCH CENTRE SURVEY OF BIOBANKS IN
EU COUNTRIES, 2010 47
TABLE 19 EUROPEAN BIOBANKS BY TYPE OF OWNERSHIP, 2010
(%) .... 47
TABLE 20 ACCESS TO THE EUROPEAN BIOBANK, 2010 (%) ... 48
BIOBANKS IN NORTHERN EUROPE ... 48
Biobanks in Nordic Countries ... 49
Biobanks in Baltic Countries .... 50
INTERNATIONAL BIOBANKS IN OTHER PARTS OF THE WORLD ... 51
CANADIAN PARTNERSHIP FOR TOMORROW PROJECT.... 51
FAR EAST BIOBANKS ... 51
China Biobank .. 52
CHAPTER SIX: DISEASE-BASED BIOBANKS 53
DISEASE-BASED BIOBANKS .. 53
GROWTH IN DISEASE-BASED BIOBANKS .... 54
TABLE 21 U.S. GROWTH IN DISEASE-BASED BIOBANKS BY
THERAPY, 1995–2008 (CUMULATIVE NO. OF BIOBANKS) ... 54
CANCER BIOBANKS . 55
BIOBANKS FOR OTHER DISEASES 56
Biobanks for Other Diseases (Continued) .... 57
HEALTHY SAMPLE BIOBANKS ... 58
COLLABORATIVE NETWORKS ... 59
ONCORE U.K. ... 60
INTERNATIONAL GENOMICS CONSORTIUM .. 60
CANCER GENOME ATLAS . 61
SEGMENT FORECAST ... 61
SEGMENT FORECAST (CONTINUED) . 62
CHAPTER SEVEN: POPULATION-BASED BIOBANKS .... 63
INTRODUCTION ... 63
TYPES OF POPULATION BIOBANKS ... 64
COHORT STUDIES .... 64
TABLE 22 SELECTED POPULATION-BASED COHORT BIOBANKS .. 65
FOUNDER POPULATION BIOBANKS ... 66
TABLE 23 FOUNDER POPULATION-BASED BIOBANKS . 67
DECODE GENETICS . 67
CARTAGENE .... 68
GENIZON BIOSCIENCES ... 68
JURILAB . 69
NATIONAL POPULATION BIOBANKS .. 69
U.K. BIOBANK . 69
U.K. Biobank (Continued) .... 70
LIFEGENE ... 71
ESTONIAN BIOBANK .... 71
LATVIAN BIOBANK .. 72
CANADIAN PARTNERSHIP FOR TOMORROW PROJECT.... 72
OTHER NATIONAL BIOBANKS .. 72
Other National Biobanks (Continued) 73
CHAPTER EIGHT: PRIVATE FOR-PROFIT BIOBANKING COMPANIES 74
CONTRACT BIOBANKING AND SERVICE PROVIDERS .. 74
CONTRACT BIOBANKING AND SERVICE … (CONTINUED) ... 75
BIOMARKER DISCOVERY COMPANIES ... 76
PHARMACEUTICAL COLLECTIONS .... 77
RESEARCH COLLABORATIONS .. 77
CLINICAL TRIALS 78
CLINICAL TRIALS (CONTINUED) ... 79
CHAPTER NINE: THE LIMITATIONS OF BIOBANKS . 80
THE LIMITATIONS OF BIOBANKS . 80
SAMPLE VARIABILITY .. 81
SAMPLE QUALITY 82
EFFORTS TO INCREASE HARMONIZATION 83
EFFORTS TO INCREASE HARMONIZATION (CONTINUED) ... 84
INITIATIVES TO IMPROVE BIOBANKS .... 85
INITIATIVES TO IMPROVE BIOBANKS (CONTINUED) .. 86
CHAPTER TEN: REGULATORY DYNAMICS, INTELLECTUAL
PROPERTY, ETHICAL CONSIDERATIONS ... 87
INTRODUCTION ... 87
ROLE OF THE FOOD AND DRUG ADMINISTRATION 87
CURRENT REGULATORY FRAMEWORK .. 88
INFORMED CONSENT ... 89
INFORMED CONSENT (CONTINUED) . 90
WITHDRAWAL AND OWNERSHIP ... 91
CONFIDENTIALITY ... 92
COMMERCIALIZATION . 93
FDA GUIDELINES FOR BIOMARKER APPLICATIONS ... 94
TABLE 24 FDA GUIDELINES FOR BIOMARKER APPLICATIONS 94
TABLE 24 (CONTINUED) . 95
EUROPEAN MEDICINES AGENCY .. 95
REGULATORY IMPACT ON DRUG SAFETY . 96
INTELLECTUAL PROPERTY AND COMPETITIVE POSITIONING .... 96
APPROVED PATENT ANALYSIS . 96
TABLE 25 ANNUAL PATENTS FILED AND APPROVED WITH
BIOMARKER CLAIMS SINCE 2005 IN U.S., EUROPE, JAPAN,
THROUGH 2015 . 97
COMPETITIVE LANDSCAPE .. 97
LATE-STAGE CLINICAL TRIALS: COMPETITIVE
POSITIONING .. 98
TABLE 26 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS
BY SERVICES AND PRODUCTS, THROUGH 2015 ($ MILLIONS) .. 98
TABLE 27 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER
DELIVERY 99
TABLE 28 REPRESENTATIVE LIST OF APPROVED BIOMARKER
PATENTS IN U.S., EUROPE, JAPAN .... 100
TABLE 28 (CONTINUED) .... 101
ETHICAL CONSIDERATIONS .... 101
SUMMARY . 101
REGULATORY IMPLICATIONS . 102
CHAPTER ELEVEN: BIOBANKING MARKETS FORECAST BY
SEGMENT AND GEOGRAPHY .... 103
TABLE 29 FORECAST GROWTH FOR BIOBANK-RELATED MARKET,
THROUGH 2015 ($ MILLIONS) .... 103
TABLE 30 GROWTH IN GLOBAL BIOBANKS BY GEOGRAPHIC
REGION, THROUGH 2015 ($ MILLIONS) . 104
CHAPTER TWELVE: DETAILED DESCRIPTIONS OF BIOMARKER
APPLICATIONS .... 105
COLORECTAL CANCER .... 105
PREDICTIVE TESTS .... 105
Cetuximab .. 105
Panitumumab . 106
Panitumumab 107
Elesclomol .. 108
Herceptin ... 108
ADDITIONAL PREDICTIVE TESTS .... 108
TABLE 31 CURRENT ACTIVE BIOMARKER TRIALS ONGOING:
ONCOLOGY . 109
TABLE 31 (CONTINUED) .... 110
TABLE 31 (CONTINUED) .... 111
TABLE 31 (CONTINUED) .... 112
TABLE 31 (CONTINUED) .... 113
BREAST CANCER 114
PROGNOSTIC TESTS ... 114
MammaPrint ... 115
TABLE 32 REPRESENTATIVE ACTIVE BIOMARKER TRIALS
ONGOING: BREAST CANCER 116
TABLE 32 (CONTINUED) .... 117
TABLE 32 (CONTINUED) .... 118
Oncotype DX ... 119
TEST ADOPTION 120
Test Adoption (Continued) . 121
OTHER PROGNOSTIC TESTS .... 122
THEROS H/I ... 122
Mammostrat ... 122
Breast Cancer Gene Expression Prognosis Profile ... 123
Insight Dx Breast Cancer Profile . 123
MapQuant Genomic Grade Index 124
PREDICTIVE TESTS .... 124
HORMONAL THERAPIES . 125
TAXANES/ANTHRACYCLINES .. 125
TRIPLE NEGATIVE BREAST CANCER ... 126
OTHER NOVEL BIOMARKERS .. 127
LUNG CANCER .... 127
INTRODUCTION . 127
PREDICTIVE TESTS .... 127
TABLE 33 REPRESENTATIVE ACTIVE BIOMARKER TRIALS
ONGOING: LUNG CANCER .... 128
TABLE 33 (CONTINUED) .... 129
TABLE 33 (CONTINUED) .... 130
Gefitinib 130
Erlotinib 131
OTHER PREDICTIVE TESTS 132
NOVEL THERAPIES 133
PROSTATE CANCER 134
PROSTATE TESTS ... 134
Prostate Px . 134
Insight Dx Prostate Profile 135
Prostate Cancer Prognostic Test .. 135
ProstaCheck .... 135
NADiA ProsVue ... 135
ANDROGEN RECEPTOR .. 136
OVARIAN CANCER .. 136
MALIGNANT MELANOMA .... 137
TABLE 34 REPRESENTATIVE ACTIVE BIOMARKER TRIALS
ONGOING: MALIGNANT MELANOMA 138
TABLE 34 (CONTINUED) .... 139
TABLE 34 (CONTINUED) .... 140
CARDIOVASCULAR . 141
CARDIOVASCULAR (CONTINUED) .... 142
TABLE 35 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:
CARDIOVASCULAR .. 143
CENTRAL NERVOUS SYSTEM .. 143
CENTRAL NERVOUS SYSTEM (CONTINUED) 144
TABLE 36 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS
DISEASE . 145
TABLE 36 (CONTINUED) .... 146
TABLE 36 (CONTINUED) .... 147
TABLE 37 BIOMARKERS/TESTS FOR OTHER NEUROLOGICAL
DISEASES ... 147
TABLE 37 (CONTINUED) .... 148
IMMUNOLOGY-AUTOIMMUNE DISEASES . 149
TABLE 38 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:
IMMUNOLOGY 149
IMMUNOLOGY .... 149
BENLYSTA: HUMAN GENOME SCIENCES . 149
EXPEDITION AND IDENTITY ALZHEIMER'S TRIAL: ELI
LILLY .... 150
CHAPTER THIRTEEN: COMPANY PROFILES . 151
ABBOTT LABORATORIES, INC. . 151
COMPANY OVERVIEW 151
PRODUCTS AND SERVICES . 151
TABLE 39 ABBOTT REPRESENTATIVE CLINICAL TRIALS
INVOLVING BIOMARKERS .... 152
COMPANY STRATEGY. 152
AFFYMETRIX, INC. .. 153
COMPANY OVERVIEW 153
PRODUCTS AND SERVICES . 153
COMPANY STRATEGY. 153
ASTERAND, PLC . 154
COMPANY OVERVIEW 154
PRODUCTS AND SERVICES . 155
TABLE 40 ASTERAND'S BIOBANK-RELATED PRODUCTS 155
COMPANY STRATEGY. 155
ASTRAZENECA, LTD. ... 155
COMPANY OVERVIEW 155
PRODUCTS AND SERVICES . 156
TABLE 41 ASTRAZENECA'S REPRESENTATIVE CLINICAL TRIALS
INVOLVING BIOMARKERS .... 156
COMPANY STRATEGY. 156
BAYER SCHERING PHARMA AG .... 157
COMPANY OVERVIEW 157
PRODUCTS AND SERVICES . 157
COMPANY STRATEGY. 157
TABLE 42 BAYER SCHERING PHARMA CLINICAL TRIAL ON BAY94-
9172 .... 158
BIOCHAIN-GENOMICS 159
COMPANY OVERVIEW 159
PRODUCTS AND SERVICES . 159
TABLE 43 BIOCHAIN'S BIOBANK-RELATED PRODUCTS .. 159
COMPANY STRATEGY. 160
BIOSTORAGE TECHNOLOGIES, INC. 160
COMPANY OVERVIEW 160
PRODUCTS AND SERVICES . 160
TABLE 44 BIOSTORAGE'S BIOBANK-RELATED PRODUCTS . 160
COMPANY STRATEGY. 161
BOEHRINGER INGELHEIM GMBH .... 161
COMPANY OVERVIEW 161
PRODUCTS AND SERVICES . 161
COMPANY STRATEGY. 161
BRISTOL-MYERS SQUIBB CO. ... 162
COMPANY OVERVIEW 162
PRODUCTS AND SERVICES . 162
TABLE 45 BRISTOL-MYERS SQUIBB'S REPRESENTATIVE
CLINICAL TRIALS INVOLVING BIOMARKERS 163
COMPANY STRATEGY. 163
DAIICHI SANKYO CO., LTD. . 163
COMPANY OVERVIEW 164
PRODUCTS AND SERVICES . 164
COMPANY STRATEGY. 164
ELI LILLY AND CO. . 165
COMPANY OVERVIEW 165
PRODUCT AND SERVICES ... 165
TABLE 46 ELI LILLY'S REPRESENTATIVE CLINICAL TRIALS
INVOLVING BIOMARKERS .... 166
COMPANY STRATEGY. 166
EXIQON LIFE SCIENCES . 167
COMPANY OVERVIEW 167
PRODUCTS AND SERVICES . 167
TABLE 47 EXIQON'S BIOBANK-RELATED PRODUCTS . 167
COMPANY OVERVIEW 167
GENTRIS CORP. .. 168
COMPANY OVERVIEW 168
PRODUCTS AND SERVICES . 168
TABLE 48 GENTRIS' BIOBANK-RELATED PRODUCTS . 168
COMPANY STRATEGY. 168
GLAXOSMITHKLINE .... 168
COMPANY OVERVIEW 169
PRODUCTS AND SERVICES . 169
TABLE 49 GLAXOSMITHKLINE'S REPRESENTATIVE CLINICAL
TRIALS INVOLVING BIOMARKERS .... 169
COMPANY STRATEGY. 169
JOHNSON & JOHNSON, LTD. .... 170
COMPANY OVERVIEW 170
PRODUCTS AND SERVICES . 171
COMPANY STRATEGY. 171
MILLENIUM PHARMACEUTICALS .... 171
COMPANY OVERVIEW 172
PRODUCTS AND SERVICES . 172
TABLE 50 MILLENNIUM'S BIOBANK-RELATED PRODUCTS 172
COMPANY STRATEGY. 172
MERCK & CO. . 172
COMPANY OVERVIEW 172
PRODUCTS AND SERVICES . 173
TABLE 51 MERCK'S REPRESENTATIVE CLINICAL TRIALS
INVOLVING BIOMARKERS .... 173
COMPANY STRATEGY. 173
NOVARTIS AG 174
COMPANY OVERVIEW 174
PRODUCTS AND SERVICES . 175
TABLE 52 NOVARTIS' REPRESENTATIVE CLINICAL TRIALS
INVOLVING BIOMARKERS .... 175
COMPANY STRATEGY. 175
PFIZER, INC. ... 176
COMPANY OVERVIEW 176
PRODUCTS AND SERVICES . 176
TABLE 53 PFIZER'S REPRESENTATIVE CLINICAL TRIALS
INVOLVING BIOMARKERS .... 177
COMPANY STRATEGY. 177
ROCHE, LTD. .. 177
COMPANY OVERVIEW 178
PRODUCTS AND SERVICES . 178
TABLE 54 ROCHE'S REPRESENTATIVE CLINICAL TRIALS
INVOLVING BIOMARKERS .... 178
COMPANY STRATEGY. 178
SANOFI-AVENTIS .... 179
COMPANY OVERVIEW 179
PRODUCTS AND SERVICES . 179
TABLE 55 SANOFI-AVENTIS' REPRESENTATIVE CLINICAL TRIALS
INVOLVING BIOMARKERS .... 180
COMPANY STRATEGY. 181
SCIPAC ... 181
COMPANY OVERVIEW 182
PRODUCTS AND SERVICES . 182
TABLE 56 SCIPAC'S BIOBANK-RELATED PRODUCTS .. 182
COMPANY STRATEGY. 182
TAKEDA PHARMACEUTICALS, LTD. . 182
COMPANY OVERVIEW 183
PRODUCTS AND SERVICES . 183
COMPANY STRATEGY. 183
TEVA PHARMACEUTICAL INDUSTRIES, LTD. .... 184
COMPANY OVERVIEW ..... 184
PRODUCTS AND SERVICES . 185
COMPANY STRATEGY. 186
To order this report:
Biotechnology Industry: Biobanking: Technologies and Global Markets
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article